[Effect of treatment with 15/R/15-methyl derivative of prostaglandin E2 on aspirin- and indomethacin-induced damage of the mucous membrane of the upper digestive tract in rheumatoid arthritis patients].
T
T
Mach
J
J
Bogdał
J
J
Stachura
S
S
Kirchmayer
D000328:Adult; D000368:Aged; D001101:Arbaprostil / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects; D005756:Gastritis / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011459:Prostaglandins E, Synthetic / Q000627:therapeutic use*
D011459:Prostaglandins E, Synthetic; D001101:Arbaprostil; D001241:Aspirin; D007213:Indomethacin
Wpływ leczenia 15/R/15-metylowa pochodna prostaglandyny E2 na poaspirynowe i poindometacynowe uszkodzenie błony śluzowej górnego odcinka przewodu pokarmowego u chorych na reumatoidalne zapalenie stawów.